Exhibit 99.1

Theragenics® Reports Highest Annual Revenue in its History

2010 REVENUE GROWS 11% IN THE FOURTH QUARTER AND 5% FOR THE YEAR

BUFORD, Ga.--(BUSINESS WIRE)--February 15, 2011--Theragenics Corporation (NYSE: TGX), a medical device company serving the surgical products and prostate cancer treatment markets,, today announced consolidated financial results for the fourth quarter and year ended December 31, 2010, reporting the highest consolidated annual revenue in the Company’s history.

“We are pleased to enter 2011 by reporting another year of record revenue performance. In spite of a challenging economy and ongoing uncertainty in the healthcare segment, our consolidated revenue hit an all-time high. Our surgical products segment continues to produce increasing revenue and the downward trend that had significantly impacted our brachytherapy business has showed signs of stabilizing. In fact, fourth quarter was our second consecutive quarter of year over year product revenue growth in brachytherapy, after almost five years of such declines,” states M. Christine Jacobs, Chairman and CEO. “In addition, we completed the move to a new needle manufacturing facility and continued implementation of our new ERP system – both examples of how we continue to seek ways to improve profitability and efficiency, and ultimately, enhance shareholder value.”

Highlights

  • Consolidated revenue of $20.7 million in the fourth quarter represented an 11% increase over 2009. For the year, consolidated revenue of $82.2 million was the highest annual revenue in our history and an increase of 5% over 2009.
    • Surgical products segment revenue increased 12% in the fourth quarter of 2010 over fourth quarter 2009. For the year, surgical products segment revenue increased 10% over 2009.
    • Brachytherapy segment revenue increased 8% in the fourth quarter of 2010 over 2009. For the year, brachytherapy segment revenue decreased 5% from 2009.
  • Earnings per share in 2010 were $0.01 in the fourth quarter and $0.06 for the year, compared to 2009 EPS of $0.01 in the fourth quarter and $0.09 for the year.
  • Special items occurring in 2010 and their effect on earnings per share include:
    • Pre-tax charges for accounts receivables due from Core Oncology for which we believe collection is doubtful totaling $1.1 million in the fourth quarter and $2.0 million for the year. These charges affected both our brachytherapy and surgical products segments.
    • Pre-tax expenses associated with our legal action against the former owner of CP Medical totaling $20,000 in the fourth quarter and $629,000 for the year.
    • Pre-tax moving related expenses in connection with our new needle manufacturing facility totaling $570,000 for the year. No moving related expenses were incurred in the fourth quarter.
    • Other income related to the settlement of our legal action totaling $200,000 before income taxes for the fourth quarter and for the year.
    • These special items had the effect of reducing our EPS by $0.02 in the fourth quarter and $0.06 for the year.
  • On February 1, 2011, we announced the termination of our brachytherapy supply and reseller agreement with Core Oncology. Sales to Core represented 14% of brachytherapy segment revenue and 5% of consolidated revenue in 2010.
  • Capital expenditures were $1.1 million in the quarter and $9.1 million for the year 2010, primarily reflecting our investments in our new specialty needle manufacturing facility and our corporate-wide information technology (“IT”) initiative. Construction of our new facility was completed in the third quarter of 2010. Remaining payments on the construction are not expected to be material.
  • At December 31, 2010 we had cash, cash equivalents, and marketable securities of $40.6 million and outstanding borrowings under our credit agreement of $27.0 million for a net positive position of $13.6 million.

The following information was filed by Theragenics Corp (TGX) on Tuesday, February 15, 2011 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one year to another to evaluate Theragenics Corp's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Theragenics Corp.

Continue

Never Miss A New SEC Filing Again


Real-Time SEC Filing Notifications
Screenshot taken from Gmail for a new 10-K Annual Report
Last10K.com Member Feature

Receive an e-mail as soon as a company files an Annual Report, Quarterly Report or has new 8-K corporate news.

Continue

We Highlighted This SEC Filing For You


SEC Filing Sentiment Analysis - Bullish, Bearish, Neutral
Screenshot taken from Wynn's 2018 10-K Annual Report
Last10K.com Member Feature

Read positive and negative remarks made by management in their entirety without having to find them in a 10-K/Q.

Continue

Widen Your SEC Filing Reading Experience


Increased Reading Area for SEC Filings
Screenshot taken from Adobe Inc.'s 10-Q Quarterly Report
Last10K.com Member Feature

Remove data columns and navigations in order to see much more filing content and tables in one view

Continue

Uncover Actionable Information Inside SEC Filings


SEC Filing Disclosures
Screenshot taken from Lumber Liquidators 10-K Annual Report
Last10K.com Member Feature

Read both hidden opportunities and early signs of potential problems without having to find them in a 10-K/Q

Continue

Adobe PDF, Microsoft Word and Excel Downloads


Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshots of actual 10-K and 10-Q SEC Filings in PDF, Word and Excel formats
Last10K.com Member Feature

Export Annual and Quarterly Reports to Adobe PDF, Microsoft Word and Excel for offline viewing, annotations and analysis

Continue

FREE Financial Statements


Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshot of actual balance sheet from company 10-K Annual Report
Last10K.com Member Feature

Get one-click access to balance sheets, income, operations and cash flow statements without having to find them in Annual and Quarterly Reports

Continue for FREE

Intrinsic Value Calculator


Intrinsic Value Calculator
Screenshot of intrinsic value for AT&T (2019)
Last10K.com Member Feature

Our Intrinsic Value calculator estimates what an entire company is worth using up to 10 years of financial ratios to determine if a stock is overvalued or not

Continue

Financial Stability Report


Financial Stability Report
Screenshot of financial stability report for Coco-Cola (2019)
Last10K.com Member Feature

Our Financial Stability reports uses up to 10 years of financial ratios to determine the health of a company's EPS, Dividends, Book Value, Return on Equity, Current Ratio and Debt-to-Equity

Continue

Get a Better Picture of a Company's Performance


Financial Ratios
Available Financial Ratios
Last10K.com Member Feature

See how over 70 Growth, Profitability and Financial Ratios perform over 10 Years

Continue

Log in with your credentials

or    

Forgot your details?

Create Account